Stocks and Investing Stocks and Investing

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Q2 2025 Earnings Call Transcript


Published on 2024-12-11 08:42:25 - MSN
  Print publication without navigation

  • Q2 2025 Earnings Call Transcript December 10, 2024 ImmunoPrecise Antibodies Ltd. misses on earnings expectations. Reported EPS is $-0.09 EPS, expectations were $-0.07. Operator: Good morning, ladies and gentlemen,

The article provides a transcript of the Q2 2025 earnings call for ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA). During the call, CEO Dr. Jennifer Bath discussed the company's financial performance, highlighting a revenue increase to $6.7 million, up 17% from the previous year, driven by growth in their BioStrand and Talem segments. She also mentioned the company's strategic focus on enhancing their AI-driven drug discovery platform, LENSai, which aims to accelerate the development of therapeutic antibodies. Dr. Bath outlined plans for expanding their service offerings, improving operational efficiencies, and advancing their proprietary technology. The call also covered updates on ongoing partnerships, new client engagements, and the company's outlook for the remainder of the fiscal year, emphasizing continued investment in technology and innovation to drive future growth.

Read the Full MSN Article at:
[ https://www.msn.com/en-us/technology/biotechnology/immunoprecise-antibodies-ltd-nasdaq-ipa-q2-2025-earnings-call-transcript/ar-AA1vFmlO ]